Top 300 Quiz 8

IMIQUIMOD

generic

Zyclara

IMIQUIMOD

Dosage Forms

Topical Cream

IMIQUIMOD

Topical Cream

2.5%, 3.75%, 5%

IMIQUIMOD

Common FDA Label Indication, Dosing, and Titration

Actinic keratosis

Condyloma acuminatum

Superficial basal cell carcinoma

IMIQUIMOD

MOA

Toll-like receptor 7 agonist that induces cytokines, including interferon-alpha and others

IMIQUIMOD

Adverse Reactions

Local itching

burning

erythema

xeroderma

Exfoliative dermatitis

hyperpigmentation

scrotal pain

urinary retention

IMIQUIMOD

Key Patient Counseling Points

Apply at bedtime and leave on skin for 8 h → when you get up, wash

Do not cover treated skin areas with bandages

Apply on same days of each wk

increase sensitivity to sun

PREDNISONE

generic

Deltasone

PREDNISONE

Dosage Forms

Oral Tablet

Oral Tablet, Delayed Release

Oral Solution

PREDNISONE

Oral Tablet

1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg

PREDNISONE

Oral Tablet, Delayed Release

1 mg, 2 mg, 5 mg

PREDNISONE

Oral Solution

5 mg/1 mL

5 mg/5 mL

PREDNISONE

Common FDA Label Indication, Dosing, and Titration

Allergic states

Dermatologic diseases

Endocrine disorders

GI diseases

Hematologic disorders

Neoplastic diseases

Nervous system

Renal diseases

Respiratory diseases

Rheumatic disorders

PREDNISONE

MOA

Adrenal Corticosteroid

PREDNISONE

Contraindications

Hypersensitivity to glucocorticosteroids

administration of live vaccines

systemic fungal infections

PREDNISONE

Adverse Reactions

GI upset

Primary adrenocortical insufficiency

Cushing syndrome

increased risk of infection

PREDNISONE

Key Patient Counseling Points

Take with food or milk to prevent GI upset

Take in the morning

For high-dose or longer-term treatment, monitor

INFLIXIMAB

generic

Remicade

Renflexis

Avsola

Zymfentra

INFLIXIMAB

Dosage Forms

Single-Dose Vial

Syringe

INFLIXIMAB

Single-Dose Vial

100 mg

INFLIXIMAB

Syringe

120 mg/mL

INFLIXIMAB

Common FDA Label Indication, Dosing, and Titration

Ankylosing spondylitis

Crohn disease and ulcerative colitis

Plaque psoriasis and psoriatic arthritis

Rheumatoid arthritis, with methotrexate

INFLIXIMAB

MOA

Chimeric monoclonal antibody→ inactivates human tumor necrosis factor alpha

INFLIXIMAB

Box Warnings

Malignancy

serious infections

latent tuberculosis

INFLIXIMAB

Contraindications

Doses >5 mg/kg in patients with moderate to severe heart failure

INFLIXIMAB

Adverse Reactions

Abdominal pain, bronchitis

infusion reactions

upper respiratory tract infection

autoimmune hepatitis

lupus-like syndrome

serum sickness, tuberculosis

INFLIXIMAB

Key Patient Counseling Points

Notify HCP if you start to feel any allergic-type reactions during intravenous infusion

Ensure all vaccinations are current prior to starting therapy

MIDAZOLAM C-IV

generic

Versed, Nayzilam

MIDAZOLAM C-IV

Dosage Forms

Vial

Preservative-Free Vial

Solution, Intravenous

MIDAZOLAM C-IV

Vial

2 mg/2 mL

5 mg/5 mL

10 mg/10 mL

5 mg/1 mL

10 mg/2 mL

25 mg/5 mL

50 mg/10 mL

MIDAZOLAM C-IV

Preservative-Free Vial

2 mg/2 mL

5 mg/1 mL

5 mg/5 mL

10 mg/2 mL

MIDAZOLAM C-IV

Solution, Intravenous

100 mg/100 mL

50 mg/50 mL

MIDAZOLAM C-IV

Common FDA Label Indication, Dosing, and Titration

Preoperative sedation, anxiolysis, amnesia

MIDAZOLAM C-IV

MOA

Enhanced postsynaptic effect of the inhibitory neurotransmitter, GABA

MIDAZOLAM C-IV

Dose Adjustment Renal

yes

MIDAZOLAM C-IV

Box Warnings

Respiratory depression with concomitant opioids

dosage individualization

personnel/equipment available for resuscitation

rapid injection in neonates

risk of abuse/misuse/addiction

dependence and withdrawal

MIDAZOLAM C-IV

Contraindications

narrow-angle glaucoma

MIDAZOLAM C-IV

Adverse Reactions

Slow breathing rate

decreased tidal volume

apnea

Cardiac arrest

MIDAZOLAM C-IV

Key Patient Counseling Points

Notify HCP of all medication use, including alcohol and OTC

Avoid driving

RITUXIMAB

generic

Riabni

Truxima

Ruxience

Rituxan Hycela

RITUXIMAB

Dosage Forms

Solution Intravenous

Solution subcutaneous

RITUXIMAB

Solution subcutaneous

rituximab 1400 mg and hyaluronidase human 23,400 units per 11.7 mL

rituximab 1600 mg and hyaluronidase human 26,800 units per 13.4 mL

rituximab 1400 mg and hyaluronidase human 23,400 units per 11.7 mL

RITUXIMAB

Solution Intravenous

100 mg/10 mL

500 mg/50 mL

RITUXIMAB

Common FDA Label Indication, Dosing, and Titration

Granulomatosis with polyangiitis and microscopic polyangiitis

Moderate to severe pemphigus vulgaris

Rheumatoid arthritis

Chronic lymphocytic leukemia

Non-Hodgkin lymphoma

Follicular lymphoma

RITUXIMAB

MOA

chimeric monoclonal antibody that is directed toward the CD20 antigen on B-lymphocytes

RITUXIMAB

Box Warnings

Infusion reactions

severe mucocutaneous reactions

hepatitis B reactivation

PML

RITUXIMAB

Adverse Reactions

asthenia

infusion reactions, leukopenia, lymphopenia, neutropenia

night sweats

GI perforation

nephrotoxicity

PML

toxic epidermal necrosis

tumor lysis syndrome

RITUXIMAB

Key Patient Counseling Points

Infusion reactions are common

Females should avoid pregnancy while on treatment and for 12 mo after

use effective contraception while on treatment